Genetic variants impacting metabolic outcomes among people on clozapine: a systematic review and meta-analysis

2017 ◽  
Vol 234 (20) ◽  
pp. 2989-3008 ◽  
Author(s):  
Rachel J. Suetani ◽  
Dan Siskind ◽  
Heidi Reichhold ◽  
Steve Kisely
Keyword(s):  
Systematic Review ◽  
Genetic Variants ◽  
Meta Analysis ◽  
Metabolic Outcomes

Genetic variants associated with methotrexate-induced mucositis in cancer treatment: a systematic review and meta-analysis

2021 ◽  
pp. 103312
Author(s):  
Hedy Maagdenberg ◽  
Natanja Oosterom ◽  
Jolanda Zanen ◽  
Donato Gemmati ◽  
Rachael E. Windsor ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cancer Treatment ◽  
Genetic Variants ◽  
Meta Analysis

scholarly journals Identification of genetic variants associated with dengue or West Nile virus disease: a systematic review and meta-analysis

2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Megan E. Cahill ◽  
Samantha Conley ◽  
Andrew T. DeWan ◽  
Ruth R. Montgomery
Keyword(s):  
Systematic Review ◽  
West Nile Virus ◽  
Genetic Variants ◽  
Virus Disease ◽  
Meta Analysis ◽  
West Nile

scholarly journals Genetic Association Studies of Red Blood Cell Transfusion Related Alloimmunization: A Systematic Review and Meta-Analysis

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 2459-2459
Author(s):  
Jorn Gerritsma ◽  
Ilja Oomen ◽  
Sanne Meinderts ◽  
C. Ellen van der Schoot ◽  
Bart J. Biemond ◽  
...  
Keyword(s):  
Systematic Review ◽  
Genetic Variants ◽  
Screening Tool ◽  
Association Studies ◽  
Data Extraction ◽  
Meta Analysis ◽  
Genetic Association Studies ◽  
Risk Of Bias ◽  
Cell Disease

Introduction: Blood transfusions are an important treatment modality for patients with either acute or chronic onset anemia such as trauma, sickle cell disease, and hematological malignancies. Transfusion poses a risk for alloimmunization, which may lead to potentially lethal transfusion reactions. A promising strategy to prevent alloimmunization is extensive matching on blood groups, yet this is a costly procedure and should be reserved for patients at highest risk for alloimmunization. Identification of genetic variants that increase the risk for alloimmunization might help to identify high-risk patients and could be used as a screening tool for patients receiving multiple transfusions. Objectives: To summarize all available evidence on genetic risk factors for alloimmunization after blood transfusion. Design: Systematic review with meta-analysis of observational studies. Studies were only included in the meta-analysis if polymorphisms were tested at least 3 times, and if ethnic background of the population and the control populations were comparable between studies. Data sources: The online databases Embase, MEDLINE and the Cochrane Library were search for relevant articles with search terms: 1) transfusion, 2) alloimmunization 3) genetics. The search was last updated March 2018. Eligibility criteria: 1) Primary study that assessed the association of genetic polymorphisms with transfusion related alloimmunization, 2) a human population, 3) studies with at least 50 patients, 4) full text availability. Data extraction: Two reviewers independently screened articles for eligibility, extracted data using a standardized data extraction form. Extracted data included study setting, study population, participant demographics, baseline characteristics, study methodology, comparisons and outcome, and risk of bias. Primary outcome measure: Alloimmunization after one or more blood transfusions. Risk of bias assessment: The quality of the included studies was assessed by the Q-genie tool for genetic association studies. Results: A total of 2045 cases and 24084 controls were derived from 18 genetic case-control studies that were included in this systematic review. Most commonly studied disease group was sickle cell disease (SCD) (8 studies). Three studies included patients with different diseases and seven studies did not report the underlying disease. Eleven studies identified the association of HLA polymorphisms with alloimmunization and 8 studies focused on non-HLA variants. Overall quality of the included studies was moderate (11 studies), 2 studies were of high quality, and 5 studies were ranked as poor. HLA-DRB1*04 (Odds Ratio 7.16, 95%CI 3.87-13.22, P<0.00001) and HLA-DRB1*15 (OR 3.01, 95%CI 1.84-5.53, P<0.0001) were by meta-analysis significantly associated with anti-Fy(a) formation, although there was considerable heterogeneity (I2=78% and 55% respectively). Moreover, HLA-DRB1*10 (OR 2.64, 95%CI 1.41-4.95, P=0.002), HLA*DRB1*11 (OR 2.11, 95%CI 1.34-3.32, P=0.001), and HLA-DRB1*13 (OR 1.71, 95%CI 1.26-2.33, P=0.0006) were overall associated with anti-Kell formation. Heterogeneity was less prominent with an I2 of 0%, 54% and 19% respectively (Figure 1). No other variants were eligible for meta-analysis. Non-HLA variants were tested less extensively, as most variants were reported by only 1 study. Polymorphisms of genes in the immunomodulatory pathways were assessed most frequently. Of these variants, FC-gamma-receptor 2C.nc-ORF was associated with a decreased risk of alloimmunization in SCD (OR 0.26, 95%CI 0.11-0.64, p=0.003). All other associations that were described as significant by the original articles were summarized in Figure 2. Discussion: There is limited evidence supporting the role of genetic risk factors for alloimmunization. The results of our meta-analysis suggest that several HLA polymorphisms potentially influence antigen presentation of the Duffy(a) and Kell antigen. Once confirmed by experimental studies, these polymorphisms could be used as a screening tool for the prevention of alloimmunization among frequently transfused patients. Overall, the effect of genetic variants on alloimmunization has mostly been assessed by small studies, hampering reliable interpretation of the results. Future studies should include large and well-defined cohorts when performing genetic analysis on this complicated subject. Disclosures No relevant conflicts of interest to declare.

The effect of omentectomy added to bariatric surgery on metabolic outcomes: a systematic review and meta-analysis of randomized controlled trials

2018 ◽  
Vol 14 (11) ◽  
pp. 1766-1782 ◽  
Author(s):  
Yung Lee ◽  
Michał Pędziwiatr ◽  
Piotr Major ◽  
Karanbir Brar ◽  
Aristithes G. Doumouras ◽  
...  
Keyword(s):  
Systematic Review ◽  
Bariatric Surgery ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Metabolic Outcomes

Evaluation of Metabolic Outcomes Following SADI-S: a Systematic Review and Meta-analysis

2022 ◽  
Author(s):  
Kevin Verhoeff ◽  
Valentin Mocanu ◽  
Aiden Zalasky ◽  
Jerry Dang ◽  
Janice Y. Kung ◽  
...  
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Metabolic Outcomes

A443 Systematic review and meta-analysis of the impact of revisional bariatric surgery on obesity-related metabolic outcomes

2019 ◽  
Vol 15 (10) ◽  
pp. S181-S182
Author(s):  
Asim Shabbir ◽  
Zong Jie Koh ◽  
Claire Chew ◽  
Nicholas Syn ◽  
Guowei Kim ◽  
...  
Keyword(s):  
Systematic Review ◽  
Bariatric Surgery ◽  
Meta Analysis ◽  
Revisional Bariatric Surgery ◽  
Metabolic Outcomes ◽  
The Impact

The association of genetic variants of matrix metalloproteinases with abdominal aortic aneurysm: a systematic review and meta-analysis

Heart ◽  
2013 ◽  
Vol 100 (4) ◽  
pp. 295-302 ◽  
Author(s):  
Dylan R Morris ◽  
Erik Biros ◽  
Oliver Cronin ◽  
Helena Kuivaniemi ◽  
Jonathan Golledge
Keyword(s):  
Systematic Review ◽  
Abdominal Aortic Aneurysm ◽  
Aortic Aneurysm ◽  
Matrix Metalloproteinases ◽  
Genetic Variants ◽  
Meta Analysis ◽  
Abdominal Aortic

Effects of Melissa officinalis (Lemon Balm) on cardio‐metabolic outcomes: A systematic review and meta‐analysis

2020 ◽  
Vol 34 (12) ◽  
pp. 3113-3123 ◽  
Author(s):  
Javad Heshmati ◽  
Mojgan Morvaridzadeh ◽  
Mahdi Sepidarkish ◽  
Siavash Fazelian ◽  
Mehran Rahimlou ◽  
...  
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Melissa Officinalis ◽  
Lemon Balm ◽  
Metabolic Outcomes

scholarly journals Genetic Variants Affecting Anti-VEGF Drug Response in Polypoidal Choroidal Vasculopathy Patients: A Systematic Review and Meta-Analysis

Genes ◽  
2020 ◽  
Vol 11 (11) ◽  
pp. 1335
Author(s):  
Xando Díaz-Villamarín ◽  
David Blánquez-Martínez ◽  
Ana Pozo-Agundo ◽  
Ana María Pérez-Gutiérrez ◽  
José Ignacio Muñoz-Ávila ◽  
...  
Keyword(s):  
Systematic Review ◽  
Treatment Response ◽  
Genetic Variants ◽  
Polypoidal Choroidal Vasculopathy ◽  
Drug Response ◽  
Meta Analysis ◽  
Age Related Macular Degeneration ◽  
Anti Vegf ◽  
Arms2 A69s ◽  
Choroidal Vasculopathy

Polypoidal choroidal vasculopathy (PCV) is usually regarded as a subtype of choroidal neovascularization (CNV) that is secondary to age-related macular degeneration (AMD) characterized by choroidal vessel branching, ending in polypoidal lesions. Despite their close association, PCV and neovascular AMD have shown differences, especially regarding patients’ treatment response. Currently, antivascular endothelial growth factor (anti-VEGF) drugs, such as ranibizumab, bevacizumab and aflibercept, have demonstrated their efficacy in CNV patients. However, in PCV, anti-VEGF treatments have shown inconclusive results. Many genetic polymorphisms have been associated with a variable response in exudative/wet AMD patients. Thus, the aim of this study is to explore the genetic variants affecting anti-VEGF drug response in PCV patients. In this regard, we performed a systematic review and meta-analysis. We found four variants (CFH I62V, CFH Y402H, ARMS2 A69S, and HTRA1-62A/G) that have been significantly related to response. Among them, the ARMS2 A69S variant is assessed in our meta-analysis. In conclusion, in order to implement anti-VEGF pharmacogenetics in clinical routines, further studies should be performed, distinguishing physio-pathogenic circumstances between PCV and exudative AMD and the combined effect on treatment response of different genetic variants.

Sign in / Sign up

Export Citation Format

Share Document